The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of 
Advanced EGFR Mutant Non-small Cell Lung Cancer Patients

Por Yuxiang MA, Yan HUANG, Hongyun ZHAO, Junling LIU, Likun CHEN, Haiying WU, Ningning ZHOU
Publicado em 2013-04-01

A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China

Por Yunpeng Yang, Yuxiang Ma, Jin Sheng, Yan Huang, Yuanyuan Zhao, Wenfeng Fang, Shaodong Hong, Ying Tian, Cong Xue, Li Zhang
Publicado em 2016-04-01

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)

Por Zhonghan Zhang, Fan Luo, Yang Zhang, Yuxiang Ma, Shaodong Hong, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang, Hongyun Zhao
Publicado em 2019-11-01

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study

Por Shen Zhao, Shen Zhao, Shen Zhao, Zhen Zhang, Zhen Zhang, Zhen Zhang, Zhen Zhang, Wenfeng Fang, Wenfeng Fang, Wenfeng Fang, Yaxiong Zhang, Yaxiong Zhang, Yaxiong Zhang, Zhonghan Zhang, Zhonghan Zhang, Zhonghan Zhang, Shaodong Hong, Shaodong Hong, Shaodong Hong, Yuxiang Ma, Yuxiang Ma, Yuxiang Ma, Ting Zhou, Ting Zhou, Ting Zhou, Yunpeng Yang, Yunpeng Yang, Yunpeng Yang, Yan Huang, Yan Huang, Yan Huang, Hongyun Zhao, Hongyun Zhao, Hongyun Zhao, Li Zhang, Li Zhang, Li Zhang
Publicado em 2020-11-01

Combinatorial assessment of ctDNA release and mutational burden predicts anti‐PD(L)1 therapy outcome in nonsmall‐cell lung cancer

Por Wenfeng Fang, Yuxiang Ma, Jiani C. Yin, Huaqiang Zhou, Fufeng Wang, Hua Bao, Ao Wang, Xue Wu, Shaodong Hong, Yunpeng Yang, Yan Huang, Hongyun Zhao, Yang W. Shao, Li Zhang
Publicado em 2020-03-01

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cance...

Por Zhonghan Zhang, Yang Zhang, Fan Luo, Yuxiang Ma, Wenfeng Fang, Jing Zhan, Su Li, Yunpeng Yang, Yuanyuan Zhao, Shaodong Hong, Ting Zhou, Yaxiong Zhang, Shen Zhao, Yan Huang, Hongyun Zhao, Li Zhang
Publicado em 2020-06-01

Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients

Por Chao Fang, Chao Fang, Wenfeng Fang, Liqin Xu, Liqin Xu, Fangfang Gao, Yong Hou, Yong Hou, Hua Zou, Yuxiang Ma, Janne Marie Moll, Yunpeng Yang, Dan Wang, Yan Huang, Huahui Ren, Huahui Ren, Hongyun Zhao, Shishang Qin, Huanzi Zhong, Huanzi Zhong, Junhua Li, Junhua Li, Sheng Liu, Huanming Yang, Huanming Yang, Jian Wang, Jian Wang, Susanne Brix, Karsten Kristiansen, Karsten Kristiansen, Karsten Kristiansen, Li Zhang
Publicado em 2022-04-01

Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing

Por Yaxiong Zhang, Lianpeng Chang, Yunpeng Yang, Wenfeng Fang, Yanfang Guan, Aiwei Wu, Shaodong Hong, Huaqiang Zhou, Gang Chen, Xi Chen, Shen Zhao, Qiufan Zheng, Hui Pan, Lanjun Zhang, Hao Long, Haoxian Yang, Xin Wang, Zhesheng Wen, Junye Wang, Hong Yang, Xuefeng Xia, Yuanyuan Zhao, Xue Hou, Yuxiang Ma, Ting Zhou, Zhonghan Zhang, Jianhua Zhan, Yan Huang, Hongyun Zhao, Ningning Zhou, Xin Yi, Li Zhang
Publicado em 2019-01-01